MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-014-1694-8

Медицинская библиотека · International journal of hematology · 2014

Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.

Okamura Ikue, Imai Hisao, Mori Keita, Ogura Kazuto, Isoda Atsushi, Mihara Keichiro, Matsumoto Morio, Saito Ryusei, Takahashi Toshiaki, Ikeda Takashi

СтатьяПеревод пока не подготовлен

Аннотация

Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare extranodal lymphoma with a 5-year survival rate of 80-95 %. There is no standard treatment strategy for pulmonary MALT lymphoma. In the present study, we performed a retrospective evaluation of systemic rituximab monotherapy (375 mg m(-2) day(-1), 4-8 cycles) as first-line treatment in patients with pulmonary MALT lymphoma. Of the eight patients enrolled, five achieved complete response, one achieved partial response, and two showed stable disease. Median progression-free survival was 66.0 months (range 9.7-87.2 months). Treatment was well tolerated and all patients were alive during the median follow-up period of 64.0 months. Rituximab monotherapy was efficacious in patients with pulmonary MALT lymphoma, demonstrating long-term disease stabilization and symptom reduction. Larger prospective studies are warranted to further assess the efficacy of rituximab monotherapy. In conclusion, rituximab monotherapy may be considered for first-line therapy in patients with pulmonary MALT lymphoma.

Для цитирования: Okamura Ikue, Imai Hisao, Mori Keita, Ogura Kazuto, Isoda Atsushi, Mihara Keichiro, Matsumoto Morio, Saito Ryusei, Takahashi Toshiaki, Ikeda Takashi. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.. International journal of hematology. 2014. DOI: 10.1007/s12185-014-1694-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.